Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Inmune Bio (INMB) over the last 7 years, with Q2 2025 value amounting to $7.3 million.

  • Inmune Bio's Gains from Investment Securities rose 1572.68% to $7.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.3 million, marking a year-over-year increase of 1572.68%. This contributed to the annual value of $7.2 million for FY2024, which is 3106.45% up from last year.
  • As of Q2 2025, Inmune Bio's Gains from Investment Securities stood at $7.3 million, which was up 1572.68% from $7.3 million recorded in Q1 2025.
  • Inmune Bio's 5-year Gains from Investment Securities high stood at $7.3 million for Q1 2025, and its period low was $198549.0 during Q1 2021.
  • Moreover, its 5-year median value for Gains from Investment Securities was $5.5 million (2023), whereas its average is $5.0 million.
  • In the last 5 years, Inmune Bio's Gains from Investment Securities tumbled by 8726.95% in 2021 and then skyrocketed by 234742.26% in 2022.
  • Inmune Bio's Gains from Investment Securities (Quarter) stood at $4.1 million in 2021, then increased by 18.17% to $4.8 million in 2022, then grew by 13.52% to $5.5 million in 2023, then skyrocketed by 31.06% to $7.2 million in 2024, then increased by 1.08% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q2 2025, $7.3 million for Q1 2025, and $7.2 million during Q4 2024.